Analyst Consensus ?
ConsensusHold22 ratings
Bullish836.4%
Neutral1463.6%
Bearish00.0%
Everest Group, Ltd. · EG · FY2025 Q2 · Calendar Q3 2025
Everest posts strong reinsurance results amid casualty remediation
The quarter supports a mixed earnings picture: strong reinsurance underwriting, specialty growth and capital deployment were offset by an Insurance underwriting loss tied to casualty remediation. The analysis supports monitoring execution on remediation and the durability of underwriting performance rather than assuming broad-based strength.
Reported After market closeNYSEFinancial Services
$14.58B market cap
90quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$17.36
Consensus $15.14
EPS surprise
+14.7%
Reported versus consensus
Reported revenue
$4.40B
Consensus $3.89B
Revenue surprise
+13.3%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+1.0%
Event window
SPY move
-0.4%
Same window
Abnormal move
+1.3%
Stock minus SPY
Volume
2.3×
Versus trailing sessions
Subsequent drift
+1.2%
Up to 20 sessions
EGSPY benchmark
Ask FN2 about EG FY2025 Q2
Transcript, numbers and history already loaded
Why did EG rise 1.0% after beating EPS estimates in FY2025 Q2?What changed in EG's guidance and outlook in FY2025 Q2?Give me the bull and bear case for EG after FY2025 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Everest continued its casualty portfolio remediation, including a 47% non-renewal rate in U.S. casualty and an $800 million reduction of casualty pro-rata business. It also repurchased $200 million of shares and indicated a faster buyback pace later in 2025.
Guidance delta
Management guidance sentiment was maintained; no quantified guidance change was supplied.
Key takeaways
- Reinsurance underwriting was strong, supported by an 85.6% combined ratio and $436 million of underwriting profit.
- Insurance recorded an underwriting loss as Everest remediated U.S. casualty exposure; specialty lines and Accident & Health grew.
- Management emphasized international expansion, specialty underwriting, capital deployment and a faster buyback pace later in 2025.
Management priorities
- Complete the 1-Renewal casualty remediation by Q3 2025.
- Expand international insurance and specialty lines.
- Invest in technology, talent and infrastructure for expense leverage.
- Deploy additional Property Cat capacity where targeted returns exceed 25%.
- Resume a higher pace of share repurchases in Q4 2025 and into 2026.
Follow EG with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$368.37Current
$332Low
$395.6Average
$485High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 10, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Mizuho | Neutral | Neutral | Maintain | Oct 7, 2026 |
| TD Cowen | Hold | Hold | Maintain | Aug 19, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 3, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 31, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Jul 31, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Jul 30, 2026 |
| Barclays | Overweight | Overweight | Maintain | Jul 30, 2026 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Jul 9, 2026 |
| Keefe, Bruyette & Woods | Outperform | Outperform | Maintain | Jul 8, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 6, 2026 |
| BMO Capital | Market Perform | Market Perform | Maintain | May 14, 2026 |
| B of A Securities | Buy | Buy | Maintain | Apr 14, 2026 |
| Wolfe Research | Peer Perform | Underperform | Upgrade | Oct 29, 2025 |
| Raymond James | Outperform | Strong Buy | Downgrade | Sep 22, 2025 |
| Jefferies | Buy | Hold | Upgrade | Apr 11, 2025 |
| Deutsche Bank | Buy | Hold | Upgrade | Mar 28, 2021 |
| Credit Suisse | Neutral | Neutral | Maintain | Nov 9, 2020 |
| CFRA | Hold | Hold | Maintain | Feb 11, 2020 |
| Goldman Sachs | Neutral | Sell | Upgrade | Nov 14, 2016 |
| Sidoti & Co. | Buy | Neutral | Upgrade | May 22, 2013 |
| Macquarie | Neutral | Outperform | Downgrade | Apr 14, 2013 |
| JP Morgan | Overweight | Neutral | Upgrade | Dec 19, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $368.37. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Mizuho Securities | Analyst unavailable | $398 | $366.84 | +8.0% | Oct 7, 2026 |
| RBC Capital | Analyst unavailable | $455 | $369.42 | +23.5% | Sep 22, 2026 |
| Rosenblatt Securities | Analyst unavailable | $455 | $369.42 | +23.5% | Sep 22, 2026 |
| UBS | Brian Meredith | $395 | $377.12 | +7.2% | Aug 3, 2026 |
| Mizuho Securities | Yaron Kinar | $416 | $375.36 | +12.9% | Jul 31, 2026 |
| Evercore ISI | Analyst unavailable | $377 | $377.19 | +2.3% | Jul 30, 2026 |
| Atlantic Equities | Analyst unavailable | $484 | $364.88 | +31.4% | Jul 15, 2026 |
| Evercore ISI | Analyst unavailable | $375 | $371.62 | +1.8% | Jul 10, 2026 |
| Cantor Fitzgerald | Ryan Tunis | $390 | $371.29 | +5.9% | Jul 9, 2026 |
| Mizuho Securities | Yaron Kinar | $418 | $371.29 | +13.5% | Jul 9, 2026 |
| Barclays | Analyst unavailable | $420 | $372.93 | +14.0% | Jul 7, 2026 |
| Morgan Stanley | Analyst unavailable | $360 | $371.35 | -2.3% | Jul 6, 2026 |
| UBS | Analyst unavailable | $355 | $358.42 | -3.6% | May 21, 2026 |
| BMO Capital | Michael Zaremski | $376 | $347.97 | +2.1% | May 14, 2026 |
| Morgan Stanley | Bob Huang | $340 | $351.54 | -7.7% | May 7, 2026 |
| UBS | Analyst unavailable | $374 | $351.26 | +1.5% | May 4, 2026 |
| Mizuho Securities | Analyst unavailable | $365 | $333.52 | -0.9% | Apr 13, 2026 |
| Mizuho Securities | Yaron Kinar | $360 | $330.76 | -2.3% | Feb 11, 2026 |
| Mizuho Securities | Analyst unavailable | $358 | $319.92 | -2.8% | Jan 14, 2026 |
| Cantor Fitzgerald | Ryan Tunis | $344 | $319.92 | -6.6% | Jan 14, 2026 |
| Wells Fargo | Elyse Greenspan | $332 | $328.38 | -9.9% | Jan 13, 2026 |
| UBS | Brian Meredith | $345 | $329.1 | -6.3% | Jan 12, 2026 |
| Barclays | Analyst unavailable | $377 | $331.43 | +2.3% | Jan 8, 2026 |
| Evercore ISI | Analyst unavailable | $365 | $330.88 | -0.9% | Jan 7, 2026 |
| Mizuho Securities | Analyst unavailable | $359 | $328.56 | -2.5% | Dec 15, 2025 |
| Raymond James | Gregory Peters | $350 | $314.52 | -5.0% | Nov 3, 2025 |
| Barclays | Analyst unavailable | $365 | $314.7 | -0.9% | Oct 31, 2025 |
| Barclays | Analyst unavailable | $425 | $343.98 | +15.4% | Oct 28, 2025 |
| Barclays | Alex Scott | $430 | $364.86 | +16.7% | Oct 8, 2025 |
| Evercore ISI | Analyst unavailable | $384 | $353.13 | +4.2% | Oct 1, 2025 |
| Raymond James | Gregory Peters | $375 | $335.38 | +1.8% | Sep 22, 2025 |
| Wells Fargo | Elyse Greenspan | $371 | $326.04 | +0.7% | Aug 4, 2025 |
| Wells Fargo | Elyse Greenspan | $362 | $340.45 | -1.7% | Jul 10, 2025 |
| Barclays | Alex Scott | $470 | $341.72 | +27.6% | Feb 4, 2025 |
| BMO Capital | Michael Zaremski | $453 | $353.52 | +23.0% | Jan 10, 2025 |
| BMO Capital | Michael Zaremski | $372 | $368.43 | +1.0% | Nov 14, 2024 |
| Bank of America Securities | Joshua Shanker | $485 | $388.89 | +31.7% | Oct 10, 2024 |
| Barclays | Alex Scott | $527 | $392.5 | +43.1% | Sep 4, 2024 |
| BMO Capital | Michael Zaremski | $403 | $360.63 | +9.4% | Aug 7, 2024 |
| Raymond James | Analyst unavailable | $385 | $356.33 | +4.5% | Feb 2, 2023 |
| Wells Fargo | Analyst unavailable | $365 | $332.95 | -0.9% | Nov 29, 2022 |
| Morgan Stanley | Analyst unavailable | $345 | $325.32 | -6.3% | Nov 22, 2022 |
| Jefferies | Analyst unavailable | $344 | $280.12 | -6.6% | Jul 12, 2022 |
Track every rating change on EG the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationEverest Group, Ltd., together with subsidiaries, provides reinsurance and insurance products in the United States, Europe, and internationally. It operates in two segment, Insurance and Reinsurance. The company writes property and casualty reinsurance; treaty and facultative reinsurance products; and specialty lines of business through reinsurance brokers, as well as directly with ceding companies; and writes property and casualty insurance directly, as well as through brokers, surplus lines, and general agents. It provides reinsurance products comprising mortgage, catastrophe, marine, aviation, engineering, professional line, credit and surety, motor, agriculture/crop, and political violence reinsurance products. In addition, the company offers commercial property and casualty insurance products through wholesale and retail brokers, surplus lines brokers, and program administrators. The company was formerly known as Everest Re Group, Ltd. and changed its name to Everest Group, Ltd. in July 2023.Everest Group, Ltd., was founded in 1973 and is headquartered in Hamilton, Bermuda.
Historical context
All EG earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| FDS FactSet Research Systems Inc. | FY2026 Q4 · Calendar Q3 2026 | +3.9% | +3.8% | FactSet reports record FY26 results as AI and MCP adoption accelerate |
| PUK Prudential plc | FY2026 Q2 · Calendar Q3 2026 | -40.9% | -0.5% | Prudential sustains growth and capital returns focus in H1 2026 |
| CM Canadian Imperial Bank of Commerce | FY2026 Q3 · Calendar Q3 2026 | +8.9% | -2.8% | CIBC Q3: Broad growth, resilient credit and expanded AI rollout |
| TD The Toronto-Dominion Bank | FY2026 Q3 · Calendar Q3 2026 | +13.8% | +1.4% | TD emphasizes growth investments alongside disciplined capital management |
Latest beats and misses
Who reports nextBeat on EPS
Get the EG recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:55.686058+00:00
- Polygon adjusted daily market bars · 2026-10-10T10:30:42.260427+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-10T10:30:42.257553+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-10. For educational purposes only; not investment advice.